TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
The Pharma Data
JULY 11, 2021
The efficacy of TAKHZYRO to prevent HAE attacks over the long term will be an important consideration for patients and physicians as they develop a treatment plan for patients that is focused on reducing the number of HAE attacks.”. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity.
52 
Let's personalize your content